item management s discussion and analysis of financial condition and results of operation 
results of operation the following table sets forth  for the three most recent fiscal years  the percentage relationship to net sales of principal items in the company s consolidated statements of operations fiscal year ended june  net sales cost of goods sold gross profit selling expenses general and administrative expenses research and development expenses litigation expense total operating expenses loss income from operations other income loss income before minority interest and income taxes minority interest in net loss income of consolidated subsidiaries loss income before provision for income taxes income tax benefit provision net loss income the following discussion and analysis provides information which the company s management believes is relevant to an assessment and understanding of the company s results of operations and financial condition 
this discussion should be read in conjunction with the consolidated financial statements and notes thereto appearing elsewhere herein 
all of the company s sales to date have been derived from the sale of medical device product  which include manufacture and distribution of ultrasonic medical device products  and laboratory and scientific products  which include ultrasonic equipment for scientific and laboratory purposes  ductless fume enclosures for filtration of gaseous emissions in laboratories and environmental control equipment for the abatement of air pollution 
fiscal years ended june  and net sales 
net sales of the company s medical device products and laboratory and scientific products increased  to  in fiscal from  in fiscal this difference in net sales is due to an increase in sales of medical device products of  to  in fiscal from  in fiscal this difference in net sales is also due to an increase in laboratory and scientific product sales of  to  in fiscal from  in fiscal the increase in sales of medical device products is due to an increase in sales of therapeutic medical device products of  plus an increase of  in sale of diagnostic medical device products 
the increase in sales of therapeutic medical device products was primarily attributable to the increased units of the sonablate in fiscal  the company sold sonablate units compared to unit in fiscal additionally  the company acquired of uk hifu at the end of the third quarter of fiscal and the company had the benefit of the fee per use revenue of  for the entire fiscal year 
the increase in sales of diagnostic medical device products was not attributable to a single customer  distributor or any other specific factor but an increase in customer demand for several products 
the increase in sales of laboratory and scientific products is primarily due to a  increase in labcaire products sales  partially offset by a  decrease in sales of wet scrubber products 
the company is being very selective in the opportunities it pursues for wet scrubber products 
the increase in labcaire sales of  is due to an increase in guardian endoscope products and services of  and the strengthening of the english pound versus the us dollar of approximately  the increase in ductless fume enclosure product sales is due to an increase in customer demand for several products and not attributable to a single customer  distributor or any other specific factor 
export sales from the united states are remitted in the us dollar and export sales for labcaire are remitted in english pounds 
ukhifu sales are remitted in english pounds and misonix  ltd 
sales to date have been remitted in euros 
to the extent that the company s revenues are generated in english pounds  its operating results were translated for reporting purposes into us dollars using weighted average rates of and for the years ended june  and  respectively 
to the extent that the company s revenues are generated in euros  its operating results were translated for reporting purposes into u 
s dollars using a weighted average rate of for the year ended june  a strengthening of the english pound and euro  in relation to the us dollar  will have the effect of increasing recorded revenues and profits  while a weakening of the english pound and euro will have the opposite effect 
since the company s operations in england generally set prices and bids for contracts in english pounds  a strengthening of the english pound  while increasing the value of its uk assets  might place the company at a pricing disadvantage in bidding for work from manufacturers based overseas 
the company collects its receivables predominately in the currency of the country the subsidiary resides in 
the company has not engaged in foreign currency hedging transactions  which include forward exchange agreements 
the company s revenues are generated from various geographic regions 
the following is an analysis of net sales by geographic region year ended june  united states united kingdom europe asia canada and mexico middle east other summarized financial information for each of the segments for the years ended june  and are as follows for the year ended june  medical devices laboratory and scientific products corporate and unallocated total net sales cost of goods sold gross profit selling expenses research and development general and administrative total operating expenses income loss from operations for the year ended june  medical devices laboratory and scientific products corporate and unallocated total net sales cost of goods sold gross profit selling expenses research and development general and administrative total operating expenses income loss from operations net sales for the three months ended june  were  compared to  for the three months ended june  this increase of  for the three months ended june  is due to an increase in sales of medical device products of  and an increase in laboratory and scientific products sales of  the increase in sales of medical device products is due to an increase in sales of diagnostic medical devices products of  and an increase of  in sales of therapeutic medical device products 
the increase in sales of diagnostic medical device products was not attributable to a single customer  distributor or any other specific factor 
the increase in sales of therapeutic medical device products was mostly attributable to an increase in sales of the company s neuroaspirator of approximately  an increase in the company s lithotripter product of approximately  an increase in the company s ultrasonic assisted liposuction product of approximately  and an increase in the company s sales of the sb product of approximately  the increase in laboratory and scientific products sales is due to an increase in labcaire products sales of  the strengthening of the english pound verses the us dollar of  an increase in ductless fume enclosure product sales of  partially offset by a decrease in wet scrubber sales of summarized financial information for each of the segments for the three months ended june  and are as follows for the three months ended june  medical devices laboratory and scientific products corporate and unallocated total net sales cost of goods sold gross profit selling expenses research and development general and administrative total operating expenses income loss from operations for the three months ended june  medical devices laboratory and scientific products corporate and unallocated total net sales cost of goods sold gross profit selling expenses research and development general and administrative total operating expenses income loss from operations gross profit 
gross profit increased to in fiscal from in fiscal gross profit for medical device products increased to in fiscal from in fiscal gross profit for laboratory and scientific products increased to in fiscal from in fiscal gross profit for medical device products was impacted by a favorable order sales mix of therapeutic medical device products  partially offset by lower gross margins on sales to uss and an unfavorable mix of diagnostic medical device products sales 
the increase in gross profit for laboratory and scientific products is due to higher gross profit for wet scrubbers  fume enclosure products and labcaire products 
gross profit increased to of sales in the three months ended june  from of sales in the three months ended june  gross profit for laboratory and scientific products increased to of sales in the three months ended june  from in the three months ended june  gross profit for medical device products increased from of sales in the three months ended june  to of sales in the three months ended june  the increase in gross profit for laboratory and scientific products was impacted predominately by increased service revenue at labcaire 
the increase in gross profit for medical device products was predominately impacted by a favorable order mix for sales of therapeutic medical device products 
the company manufactures and sells both medical device products and laboratory and scientific products with a wide range of product costs and gross margin dollars as a percentage of revenues 
selling expenses 
selling expenses increased  or to  of net sales in fiscal from  of net sales in fiscal medical device products selling expenses increased  due both to additional sales and marketing efforts for therapeutic medical device products 
laboratory and scientific products selling expenses decreased  selling expenses decreased  to  of net sales in the three months ended june  from  of net sales in the three months ended june  medical device products selling expenses decreased  due to reduced sales and marketing efforts for therapeutic medical device products 
laboratory and scientific products selling expenses increased  predominantly due to an increase in sales and marketing efforts for labcaire s isis product 
general and administrative expenses 
total corporate and unallocated expenses decreased  to  in fiscal year from  in fiscal the decrease is predominantly due to reduced stock based compensation expense of approximately  related to the adoption of statement of financial accounting standards sfas no 
r  and a reduction in corporate general and administrative expenses relating to corporate insurance  legal fees and other accrued corporate expenses 
total general and administrative expenses decreased  to  in the three months ended june  from  in the three months ended june  the decrease is predominantly due to a decrease in legal fees spent at sonora and other accrued corporate expenses 
research and development expenses 
research and development expenses decreased  to  in fiscal from  in fiscal research and development expenses related to medical device products decreased  and research and development expenses related to laboratory and scientific products deceased  research and development expenses related to medical device products decreased predominately due to reduced efforts relating to the digital upgrade project for therapeutic medical device products partially offset by those efforts expended on the new laboratory and scientific digital sonicator product 
the decrease in research and development expense relating to laboratory and scientific products is due to the reduced efforts on the labcaire isis product which was introduced and launched during fiscal and the reduced efforts for wet scrubber products 
the company is not expanding efforts for research and development on wet scrubber products 
research and development expense decreased  for the three months ended june  to  from  for the three months ended june  research and development expense related to medical device products decreased  and research and development expense related to laboratory scientific products decreased  research and development expense related to medical device products decreased predominately due to reduced efforts relating to the digital project upgrade for therapeutic medical device products  partially offset by these efforts expanded on the new laboratory and scientific digital sonicator product 
the decrease in laboratory and scientific products research and development expenses is due to reduced effort on the labcaire isis product  which was introduced and launched during fiscal  and the reduced research and development efforts for wet scrubber products 
other income expense 
other income was  in fiscal as compared to  in fiscal the decrease of  for the fiscal year was primarily due to an increase in interest expense of  partially offset by increased foreign currency exchange gains of  and increased royalty income of  the increase in interest expense is principally attributable to increased borrowings in the united states 
income taxes 
the effective tax rate is for the fiscal year ended june  as compared to an effective tax rate of for the fiscal year ended june  the fiscal year tax rate includes the release of the valuation allowance of  related to bad debt expenses which was partially offset by adjustment to state tax rates and the impact of lower foreign tax rates 
fiscal years ended june  and net sales 
net sales of the company s medical device products and laboratory and scientific products decreased  to  in fiscal from  in fiscal this difference in net sales is due to a decrease in sales of medical device products of  to  in fiscal from  in fiscal this difference in net sales is also due to a decrease in laboratory and scientific products sales of  to  in fiscal from  in fiscal the decrease in sales of medical device products is due to a decrease in sales of therapeutic medical device products of  partially offset by an increase of  in sales of diagnostic medical device products 
the increase in sales of diagnostic medical device products was not attributable to a single customer  distributor or any other specific factor  but an increase in customer demand for several products 
the decrease in sales of therapeutic medical device products was mostly attributable to a decrease in sales to byron of the lysonix device  the autosonics device sold to uss and a decrease in sales of the sonablate in europe 
sales are not recorded as revenue until the total earnings process is complete 
the decrease in sales of laboratory and scientific products is due to a decrease in labcaire sales of  an increase in sales of ultrasonic laboratory products of  a decrease in wet scrubber sales of  and a decrease in ductless fume enclosure and related products sales of  the decrease in labcaire sales of  is primarily due to the decrease in sales of the guardian endoscope cleaning product in the amount of  and the weakening of the english pound of approximately  this reduction in sales is due to less funding available from the national health system 
the increase in scientific ultrasonic sales is due to an increase in customer demand for the ultrasonic sonicator product 
the decrease in fume enclosure sales is due to lower customer demand for these types of products 
export sales from the united states are remitted in us dollars and export sales for labcaire are remitted in english pounds 
during fiscal and fiscal  the company had foreign net sales of  and  respectively  representing of net sales for each year  respectively 
approximately of the company s revenues for fiscal year were received in english pounds 
to the extent that the company s revenues are generated in english pounds  its operating results are translated for reporting purposes into us dollars using weighted average rates of and for the years ended june  and  respectively 
a strengthening of the english pound  in relation to the us dollar  will have the effect of increasing reported revenues and profits  while a weakening of the english pound will have the opposite effect 
since the company s operations in england generally set prices and bids for contracts in english pounds  a strengthening of the english pound  while increasing the value of its uk assets  might place the company at a pricing disadvantage in bidding for work from manufacturers based overseas 
the company collects its receivables in the currency of the country the subsidiary it resides in 
the company has not engaged in foreign currency hedging transactions  which include forward exchange agreements 
the company s revenues are generated from various geographic regions 
the following is an analysis of net sales by geographic region for the year ending june united states canada and mexico united kingdom europe asia middle east other summarized financial information for each of the segments for the years ended june  and are as follows for the year ended june  medical devices laboratory and scientific products corporate and unallocated total net sales cost of goods sold gross profit selling expenses research and development general and administrative total operating expenses income loss from operations for the year ended june  medical devices laboratory and scientific products corporate and unallocated total net sales cost of goods sold gross profit selling expenses research and development general and administrative total operating expenses income from operations net sales for the three months ended june  were  compared to  for the three months ended june  this decrease of  for the three months ended june  is due to a decrease in sales of medical device products of  and a decrease in laboratory and scientific products sales of  the decrease in sales of medical device product products is due to a decrease in sales of diagnostic medical device products of  and a decrease of  in sales of therapeutic medical device products 
the decrease in sales of diagnostic medical device products was not attributable to a single customer  distributor or any other specific factor 
the decrease in sales of therapeutic medical device products was mostly attributable to a decrease in sales to uss of approximately  sales to byron of approximately  and sales of the sonablate units in europe in the amount of approximately  the decrease in laboratory and scientific products sales is principally due to a decrease in wet scrubber sales of  and a decrease in labcaire sales of  the decrease in labcaire sales is primarily due to a decrease in sales of the guardian endoscopic cleaning product of approximately  and a weakening of the english pound in the amount of  summarized financial information for each of the segments for the three months ended june  and are as follows for the three months ended june  medical devices laboratory and scientific products corporate and unallocated total net sales cost of goods sold gross profit selling expenses research and development general and administrative total operating expenses income loss from operations for the three months ended june  medical devices laboratory and scientific products corporate and unallocated total net sales cost of goods sold gross profit selling expenses research and development general and administrative total operating expenses income from operations gross profit 
gross profit decreased to in fiscal from in fiscal gross profit for medical device products decreased to in fiscal from in fiscal gross profit for laboratory and scientific products decreased to in fiscal from in fiscal gross profit for medical device products was impacted by an unfavorable order mix of therapeutic medical device products  partially to lower gross margins on sales to uss  partially offset by a favorable mix of diagnostic medical device products 
the decrease in gross profit for laboratory and scientific products is due to lower gross profit for wet scrubbers  fume enclosure products and labcaire products 
gross profit decreased to of sales in the three months ended june  from of sales in the three months ended june  gross profit for laboratory and scientific products decreased to of sales in the three months ended june  from in the three months ended june  gross profit for medical device products decreased from of sales in the three months ended june  to of sales in the three months ended june  the decrease in gross profit for laboratory and scientific products was impacted by the unfavorable order mix for sales of ultrasonic products  fume enclosures  wet scrubbers and labcaire sales 
the decrease in gross profit for medical device products was impacted by an unfavorable order mix for sales of therapeutic medical device products  partially offset by a favorable order mix of diagnostic medical device products 
the company manufactures and sells both medical device products and laboratory and scientific products with a wide range of product costs and gross margin dollars as a percentage of revenues 
selling expenses 
selling expenses increased  or to  of net sales in fiscal from  of net sales in fiscal medical device products selling expenses increased  due both to additional sales and marketing efforts for diagnostic medical device products and therapeutic medical device products 
the increase in therapeutic medical device products selling expenses of  is primarily due to an increase in sales and marketing efforts relating to european distribution of our sonablate product for prostate cancer and clinical trials for the sonic one wound debrider product  which was launched in the fourth quarter fiscal and the ultrasonic bone cutter 
laboratory and scientific products selling expenses decreased  predominantly due to a reduction in marketing expenses in all product areas 
selling expenses increased  or to  of net sales in the three months ended june  from  of net sales in the three months ended june  medical device products selling expenses increased  due to additional sales and marketing efforts for therapeutic medical device products 
laboratory and scientific products selling expenses decreased  predominantly due to a decrease in all product areas  due primarily to reduction in personnel 
general and administrative expenses 
total corporate and unallocated expenses increased  to  in fiscal year from  in fiscal general and administrative expenses  which are included in corporate and unallocated expenses  increased  or to  in fiscal from  in fiscal the increase is predominantly due to recording stock based compensation expense of  related to the adoption of sfas r and an increase in corporate general and administrative expenses relating to corporate insurance  accounting fees  legal fees  other s accrued corporate expenses and an increase in administrative staff at sonora 
total corporate and unallocated expenses decreased  to  in the three months ended june  from  in the three months ended june  general and administrative expenses  which are included in corporate and unallocated expenses  increased  from  in the three months ended june  to  in the three months ended june  the increase is predominantly due to items indicated above for the full year 
corporate and unallocated expenses also include litigation expenses of  in the year and three months ended june  research and development expenses 
research and development expenses increased  or to  in fiscal from  in fiscal research and development expenses related to medical devices products decreased  and research and development expenses related to laboratory and scientific products increased  research and development expenses related to medical device products decreased predominantly due to efforts for therapeutic medical device products and a decrease in amounts paid to focus surgery in fiscal for the development work performed for the company for the treatment of kidney and liver tumors utilizing hifu and the reduced efforts related to the digital upgrade project on all our ultrasonic platform technology as compared to fiscal the increase in research and development expenses relating to laboratory and scientific products is due to increased efforts in research and development efforts for the isis product at labcaire 
isis is the new development project designed to be fully compliant with the new united kingdom regulations for the handling  cleaning and disinfecting of endoscopes 
research and development expenses decreased  or for the three months ended june  from  to  for the three months ended june  research and development expenses related to medical device products decreased  and research and development expenses related to laboratory and scientific products increased  research and development expenses related to medical device products decreased predominantly due to reduced efforts for therapeutic medical device products in the three months ended june  for the development of products for the treatment of kidney and liver tumors utilizing hifu and the efforts related to the digital upgrade project on all our ultrasonic platform technology as compared to the three months ended june  the increase in laboratory and scientific products is primarily due to increased research and development efforts for the labcaire isis project 
litigation expenses 
the company recorded a litigation expense for the fiscal year of  as compared to for the fiscal year the company recorded the litigation expense for the three months ended june  of  as compared to for the three months ended june  litigation expense relates to the jury verdict against sonora in the district court of boulder county colorado for royalties owed and future royalties on recoating transesophogeal probes which is a process performed by sonora 
other income expense 
other income was  in fiscal as compared to  in fiscal the decrease of  for the fiscal year was primarily due to a decrease in royalty income of  from uss 
other income was  in the three months ended june  as compared to  in the three months ended june  the decrease of  for the three months ended june  was primarily due to a decrease in royalty income from uss 
income taxes 
the effective tax rate is for the fiscal year ended june  as compared to an effective tax rate of for the fiscal year ended june  the effective rate for fiscal was impacted predominantly by a reduction in valuation allowances for bad debt expenses and the tax effect of implementation of sfas r with respect to incentive stock options 
critical accounting policies general financial reporting release no 
 which was released by the sec in december  requires all companies to include a discussion of critical accounting policies or methods used in the preparation of the financial statements 
note of the notes to consolidated financial statements included in the company s annual report on form k for the year ended june  includes a summary of the company s significant accounting policies and methods used in the preparation of its financial statements 
the company s discussion and analysis of its financial condition and results of operations are based upon the company s financial statements  which have been prepared in accordance with accounting principles generally accepted in the united states 
the preparation of these financial statements requires the company to make estimates and judgments that affect the reported amounts of assets  liabilities  revenues and expenses 
on an on going basis  management evaluates its estimates and judgments  including those related to bad debts  inventories  goodwill  property  plant and equipment and income taxes 
management bases its estimates and judgments on historical experience and on various other factors that are believed to be reasonable under the circumstances  the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources 
actual results may differ from these estimates under different assumptions or conditions 
the company considers certain accounting policies related to accounts receivable  inventories  property  plant and equipment  revenue recognition  goodwill  income taxes and stock based compensation to be critical policies due to the estimation process involved in each 
accounts receivable accounts receivable  principally trade  are generally due within to days and are stated at amounts due from customers  net of an allowance for doubtful accounts 
the company performs ongoing credit evaluations and adjusts credit limits based upon payment history and the customer s current credit worthiness  as determined by a review of their current credit information 
the company continuously monitors aging reports  collections and payments from customers and maintains a provision for estimated credit losses based upon historical experience and any specific customer collection issues that have been identified 
while such credit losses have historically been within expectations and the provisions established  the company cannot guarantee the same credit loss rates will be experienced in the future 
the company writes off accounts receivable when they become uncollectible 
inventories inventories are stated at the lower of cost first in  first out or market and consist of raw materials  work in process and finished goods 
management evaluates the need to record adjustments for impairments of inventory on a quarterly basis 
the company s policy is to assess the valuation of all inventories  including raw materials  work in process and finished goods 
inventory items used for demonstration purposes  rentals or on consignment are classified in property  plant and equipment 
property  plant and equipment property  plant and equipment are recorded at cost 
the company capitalizes items in excess of minor replacements and maintenance and repair expenses are charged to expense as incurred 
depreciation of property and equipment is provided using the straight line method over estimated useful lives ranging from to years 
depreciation of the labcaire building was provided using the straight line method over the estimated useful life of years 
leasehold improvements are amortized over the life of the lease or the useful life of the related asset  whichever is shorter 
the company s policy is to periodically evaluate the appropriateness of the lives assigned to property  plant and equipment and to adjust if necessary 
inventory items included in property  plant and equipment are depreciated using the straight line method over estimated useful lives of to years 
labcaire sold its owned building in the united kingdom in june in a sale and leaseback agreement with tesco 
tesco is utilizing the property to expand its operations which will require labcaire to relocate to another facility upon tesco receiving permission to expand from the local authorities 
labcaire sold the building for million and recorded a deferred gain of million which will be amortized over the year lease period 
additionally  upon tesco receiving permission to expand its facilities which is expected in the next to years  tesco will cancel the lease and require labcaire to vacate the premises 
upon labcaire vacating the premises  tesco will pay labcaire an additional million under the agreement 
revenue recognition the company records revenue upon shipment for products shipped fob shipping point 
products shipped fob destination points are recorded as revenue when received at the point of destination 
shipments under agreements with distributors are not subject to return  and payment for these shipments is not contingent on sales by the distributor 
the company recognizes revenue on shipments to distributors in the same manner as with other customers 
fees from exclusive license agreements are recognized ratably over the terms of the respective agreements 
service contract and royalty income are recognized when earned 
goodwill goodwill represents the excess of the purchase price over the fair value of the net assets acquired in connection with the company s acquisitions of the common stock of labcaire  of the common stock of sonora and the acquisitions of fibra sonics  sonic technologies  cramar and ukhifu 
on september   but effective as of august   the company and william h 
phillips phillips entered into a settlement agreement the agreement 
pursuant to the agreement  the company and phillips resolved certain disputes between them concerning the purchase price to be paid by the company for shares of the common stock of sonora owned by phillips 
the company owned ninety percent of the outstanding shares of acoustic prior to the execution of the agreement 
pursuant to the agreement  the company will pay phillips the aggregate sum of  the purchase price 
the company paid phillips  on june  and  on august  the company will pay the balance of the purchase price in two installments with the final installment due on march  the shares of acoustic being sold to the company are being held in escrow and released pro rata with each installment payment of the purchase price 
the effect of this transaction will be to increase goodwill by  decrease minority interest by  and record interest expense of  in july  the financial accounting standards board fasb issued sfas nos 
and  business combinations and goodwill and other intangible assets  respectively 
sfas replaced accounting principles board apb opinion business combinations and requires the use of the purchase method for all business combinations initiated after june  sfas requires goodwill and intangible assets with indefinite useful lives to no longer be amortized  but instead be tested for impairment at least annually and whenever events or circumstances occur that indicate goodwill might be impaired 
with the adoption of sfas  as of july   the company reassessed the useful lives and residual values of all acquired intangible assets to make any necessary amortization period adjustments 
based on that assessment  only goodwill was determined to have an indefinite useful life and no adjustments were made to the amortization period or residual values of other intangible assets 
the company completed its annual goodwill impairment tests for fiscal and in the respective fourth quarter 
there were no indicators that goodwill recorded was impaired 
income taxes income taxes are accounted for in accordance with sfas no 
 accounting for income taxes sfas no 

under this method  deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards 
deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled 
the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date 
stock based compensation prior to july   the company accounted for stock option plans sfas no 
as permitted under this standard  compensation cost was recognized using the intrinsic value method described in apb no 
apb 
effective july   the company adopted the fair value recognition provisions of sfas no 
r sfas no 
r and sec staff accounting bulletin no 
using the modified prospective transition method  therefore  prior periods have not been restated 
see note of the company s consolidated financial statements for additional information regarding stock based compensation 
liquidity and capital resources working capital at june  and june  was  and  respectively 
for the fiscal year  cash used in operations totaled  the increase in cash used in operations is predominantly due to an increase in accounts receivables and deferred income tax benefit 
for the fiscal year  cash provided by investing activities was  which primarily consisted of the proceeds from the sale and lease back of the facility in the united kingdom 
for the fiscal year  cash provided in financing activities was  primarily consisting of net proceeds of short term borrowings from the company s credit facilities  partially offset by paying off the mortgage on the labcaire property 
revolving credit facilities labcaire has a debt purchase agreement with lloyds tsb commercial finance llyods 
the amount of this facility bears interest at the bank s base rate and at june  and  respectively plus 
the agreement expires on september  and covers all united kingdom and european sales 
at june   the balance outstanding under this credit facility was  and labcaire is not in violation of financial covenants 
labcaire had an overdraft facility with lloyds which was secured by the labcaire building 
all amounts borrowed under this facility were paid when the labcaire building was sold and the overdraft credit facility was cancelled 
on december  the company and its subsidiaries  acoustic marketing research  inc d b a sonora medical systems and hearing innovations incorporated collectively referred to as the borrowers and wells fargo bank national association entered into a i credit and security agreement and ii credit and security agreement export import subfacility collectively referred to as the credit agreements 
the aggregate credit limit under the credit agreements is  consisting of a revolving facility in the amount of up to  up to  of the revolving facility is available under the export import agreements as a subfacility for export import working capital financing 
all credit facilities under the credit agreements mature on december  payment of amounts outstanding under the credit agreements may be accelerated upon to occurrence of an event of default as defined in the credit agreements 
all loans and advances under the credit agreements are secured by a first priority security interest in all of the borrowers accounts receivable  deposit accounts  property  plant and equipment  general intangibles  intellectual property  inventory  letter of credit rights  and all other business assets 
the borrowers have the right to terminate or reduce the credit facility prior to december  by paying a fee based on the aggregate credit limit or reduction  as the case may be as follows i during year one of the credit agreements   ii during year two of the credit agreements   and iii during year three of the credit agreements  
the credit agreements contain financial covenants requiring that the borrowers i on a consolidated basis not have a net loss as defined in the credit agreements of more than  for the fiscal quarter ending june   and ii not incur or contract to incur capital expenditures as defined in the credit agreements of more that  in the aggregate in any fiscal year or more than  in any one transaction 
at june   the borrowers were in compliance with the financial covenants 
the available amount under the credit agreements is the lesser of  or the amount calculated under the borrowing base as defined in the credit agreement 
the borrowers must maintain a minimum outstanding amount of  under the credit agreements at all times and pay a fee equal to the interest rate set forth on any such shortfall 
interest on amounts borrowed under payable monthly in arrears 
the default rate of interest is higher than the rate otherwise payable 
a fee of per annum on the unused amount as defined in the credit agreements is payable monthly in arrears 
at june   the balance outstanding under the credit agreements was  the amounts available to borrow are determined based on specified percentages of the borrowers eligible trade receivables and inventories 
an additional  was available to borrow at june  commitments the company has commitments under a revolving credit facility  note payable  mortgage and capital and operating leases that will be funded from operating sources 
at june   the company s contractual cash obligations and commitments relating to the revolving credit facility and capital and operating leases are as follows commitment less than year years years after years total revolving credit facility note payable capital leases operating leases labcaire sold its owned building in the united kingdom in june in a sale and leaseback agreement with tesco 
the lease with tesco expires june the rental amount is  per month 
on september   but effective as of august   the company and phillips entered into the agreement 
pursuant to the agreement  the company and phillips resolved certain disputes between them concerning the purchase price to be paid by the company for shares of the common stock of sonora owned by phillips 
the company owned ninety percent of the outstanding shares of sonora prior to the execution of the agreement 
pursuant to the agreement  the company will pay phillips the aggregate sum of  the purchase price 
the company paid phillips  on june  and  on august  the company will pay the balance of the purchase price in two installments with the final installment due on march  the shares of acoustic being sold to the company are being held in escrow and released pro rata with each installment payment of the purchase price 
the effect of this transaction will be to increase goodwill by  decrease minority interest by  and record interest expense of  off balance sheet arrangements the company has no off balance sheet arrangements that have or are reasonably likely to have a current or future effect on the company s financial condition  changes in financial condition  revenues or expenses  results of operations  liquidity  capital expenditures or capital resources that is material to the company 
other the company believes that its existing capital resources will enable it to maintain its current and planned operations for at least months from the date hereof 
in the opinion of management  inflation has not had a material effect on the operations of the company 
item a 
quantitative and qualitative disclosures about market risk market risk the principal market risks ie  the risk of loss arising from adverse changes in market rates and prices to which the company is exposed are interest rates on short term investments and foreign exchange rates  which generate translation gains and losses due to the english pound to us dollar conversion of labcaire 
foreign exchange rates approximately of the company s revenues in fiscal were received in english pounds currency 
to the extent that the company s revenues are generated in english pounds  its operating results are translated for reporting purposes into us dollars using weighted average rates of and for the fiscal year ended june  and  respectively 
a strengthening of the english pound  in relation to the us dollar  will have the effect of increasing reported revenues and profits  while a weakening of the english pound will have the opposite effect 
since the company s operations in england generally sets prices and bids for contracts in english pounds  a strengthening of the english pound  while increasing the value of its uk assets  might place the company at a pricing disadvantage in bidding for work from manufacturers based overseas 
the company collects its receivables predominately in the currency of the country the subsidiary resides in 
misonix ltd 
invoices certain customers in euros and as a result there is an exchange rate exposure between the english pound and the euro 
the company has not engaged in foreign currency hedging transactions  which include forward exchange agreements 

